Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2011 1
2014 1
2017 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
In Defense of Progesterone: A Review of the Literature.
Lieberman A, Curtis L. Lieberman A, et al. Altern Ther Health Med. 2017 Nov;23(6):24-32. Altern Ther Health Med. 2017. PMID: 29055286 Review.
Use of progesterone has been linked to lower rates of uterine and colon cancers and may also be useful in treating other cancers such as ovarian, melanoma, mesothelioma, and prostate. Progesterone may also be helpful in preventing cardiovascular disease and preventi …
Use of progesterone has been linked to lower rates of uterine and colon cancers and may also be useful in treating other cancers such as …
Clinicopathological features and programmed death-ligand 1 immunohistochemical expression in a multicenter cohort of uterine and ovarian melanomas: a retrospective study in Japan (KCOG-G1701s).
Yano M, Nasu K, Yasuda M, Katoh T, Kagabu M, Kobara H, Matsuura M, Tokuyama O, Yamawaki T, Wakahashi S, Noguchi T, Mizuno K, Shitsukawa K, Onohara Y, Nakabori T, Miyasaka A, Nakao T, Matsunaga T, Kunimi Y, Sakurai M, Uchiyama A, Itoh R, Ohike N, Hirakawa T, Watanabe T, Nishino K, Motohashi T, Ito K. Yano M, et al. Melanoma Res. 2022 Jun 1;32(3):150-158. doi: 10.1097/CMR.0000000000000811. Epub 2022 Mar 29. Melanoma Res. 2022. PMID: 35377861
The objective of this study was to propose prognostic factors and optimal treatment strategies by analyzing the clinicopathological features and programmed death-ligand 1 (PD-L1) expression. We analyzed 31 patients diagnosed with uterine or ovarian melanoma between …
The objective of this study was to propose prognostic factors and optimal treatment strategies by analyzing the clinicopathological features …
Effects of individual-level socioeconomic factors on racial disparities in cancer treatment and survival: findings from the National Longitudinal Mortality Study, 1979-2003.
Du XL, Lin CC, Johnson NJ, Altekruse S. Du XL, et al. Cancer. 2011 Jul 15;117(14):3242-51. doi: 10.1002/cncr.25854. Epub 2011 Jan 24. Cancer. 2011. PMID: 21264829 Free PMC article.
METHODS: This study included 13,234 cases diagnosed with the 8 most common types of cancer (female breast, colorectal, prostate, lung and bronchus, uterine cervix, ovarian, melanoma, and urinary bladder) at age 25 years, identified from the National Longitudinal Mor …
METHODS: This study included 13,234 cases diagnosed with the 8 most common types of cancer (female breast, colorectal, prostate, lung and br …
Expression of breast cancer metastasis suppressor-1, BRMS-1, in human breast cancer and the biological impact of BRMS-1 on the migration of breast cancer cells.
Zhang Y, Ye L, Tan Y, Sun P, Ji K, Jiang WG. Zhang Y, et al. Anticancer Res. 2014 Mar;34(3):1417-26. Anticancer Res. 2014. PMID: 24596389
Breast cancer metastasis suppressor-1 (BRMS1) is a candidate metastasis-suppressing gene and has been shown to potentially inhibit tumor progression without blocking the growth of orthotopic tumors, in different tumor types including non-small cell lung cancer, ovarian, …
Breast cancer metastasis suppressor-1 (BRMS1) is a candidate metastasis-suppressing gene and has been shown to potentially inhibit tumor pro …